Cancer Forums and News by PhD's

News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Researchers Identify New Pathway, Enhancing Tamoxifen to Tame Aggressive Breast Cancer
By Dross at 2013-04-24 23:48

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen’s secondary activities so that it

read more | 1 comment | 4009 reads

Further breakthroughs for breast cancer patients
By Dross at 2008-01-19 02:50

Researchers at the Tenovus Centre for Cancer Research at Cardiff University have made a breakthrough in breast cancer treatment that could help save the lives of women who become resistant to breast cancer drugs such as tamoxifen.

While drugs such as tamoxifen have been a huge success in treating breast cancer, for a significant proportion of sufferers the drugs either fail to work, or after an initial successful response the patient relapses as the cancer acquires or possesses resistance to the drug.

However the researchers have discovered that inhibiting the activity of a certain protein in the cancer could prevent or even reverse the resistance to tamoxifen. The researchers noticed that when breast cancer cells grown in the laboratory develop resistance to tamoxifen, they show a large increase in the activity of a protein known as Src – and by stopping this activity resistance to tamoxifen can be prevented and even reversed.

read more | 1309 reads

New Cause of Tamoxifen Resistance in Breast Cancer Cells
By Dross at 2007-08-13 00:57

When a woman receives a breast cancer diagnosis her entire life may change in the blink of an eye. But the nature of that change is governed by the smallest alterations that take place within the proteins of the tumor cells, determining what treatments she can pursue with a hope of cure and those to which her cancer is resistant.


Scientists from the Lombardi Comprehensive Cancer Center announced today the discovery of a new mechanism of resistance to endocrine or anti-hormonal therapies, such as Tamoxifen and Faslodex. This research may allow oncologists to screen women for responsiveness to these treatments, and provides a much-needed clue to reversing resistance. The research, led by Robert Clarke, PhD, DSc, a professor of oncology and of physiology and biophysics at Georgetown University Medical Center, indicates that a gene previously thought to be unrelated to breast cancer may be responsible for some resistance to endocrine therapy.

read more | 1 comment | 1378 reads

New adjuvant treatments for breast cancer prove cost-effective
By Dross at 2007-06-25 21:05

New adjuvant treatments for breast cancer are cost-effective at improving survival, according to two new studies. Published in the August 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the two studies looked at the cost-effectiveness of different drugs for the management of adjuvant therapies for early breast cancer. In a Canadian economic study of estrogen receptor positive breast cancers, switching from tamoxifen to the oral steroidal aromatase inhibitor exemestane (trade name: Aromasin) extended disease free survival at a minimal cost per person. In another of study of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the addition of the anti-HER2 receptor monoclonal antibodyterm, trastuzumab (trade name: Herceptin), is projected to improve life expectancy at a relatively low cost.

read more | 1 comment | 1736 reads

Early switch to an aromatase inhibitor increases survival
By Dross at 2007-02-12 21:49

For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates, according to a new study. Published in the March 15, 2007 issue of CANCER (, a peer-reviewed journal of the American Cancer Society, the study reveals that the clear survival benefit was also achieved without an increased risk of death from other causes,  a significant risk associated with tamoxifen. Hormone modulating therapies have made a significant impact on the survival rates of women with estrogen-sensitive breast cancer over the last two decades. The drugs are used as adjuvant to primary surgical treatment for a period of five years. Tamoxifen was the first estrogen modulator shown to increase survival and reduce the risk of breast cancer recurrence. However, tamoxifen is associated with increased risk of death from other causes, such as strokes and endometrial cancer.

read more | 6 comments | 2209 reads

Hormone drug type makes survival difference in advanced breast cancer
By Dross at 2007-01-31 05:03


Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies. In addition, aromatase inhibitors -- drugs known as Arimidex, Aromasin and Femara -- are less likely to cause blood clots and vaginal bleeding than other hormone treatments, said review co-author Judith Bliss of the Institute of Cancer Research in London. The review analyzed 30 studies involving the treatment of advanced breast cancer, encompassing more than 10,000 postmenopausal women. Bliss and colleagues were surprised at how few of the reviewed studies presented data on overall survival for women taking aromatase inhibitors.

read more | 2410 reads

Compound Boosts Tamoxifen's Cancer-Fighting Power -
By admin at 2006-12-15 04:59

[via Compound Boosts Tamoxifen's Cancer-Fighting Power -]:Adding a second drug to tamoxifen, the breast cancer drug used successfully for more than 20 years, helps it retain its full strength, scientists at the U.S. National Cancer Institute report. Over time, tamoxifen can lose its effectiveness. But the new molecule, called disulfide benzamide or DIBA, could provide a way to overcome that acquired resistance and restore tamoxifen's effectiveness. DIBA "is not a new molecule," noted William Farrar, head of the Cancer Stem Cell Section of the National Cancer Institute's Center for Cancer Research at Frederick, Md., and the study's lead author. "It's been around a while."

read more | 1218 reads

Breast cancer patients found to live longer with new drug :: - Houston Chronicle
By admin at 2006-11-22 10:19

Switching patients with early breast cancer from a standard drug to a newer treatment helps them live longer and improves their odds of remaining free of the disease, German researchers said Friday.

Although tamoxifen has been the standard treatment following surgery for women with hormone sensitive tumors, they said changing to a newer class of drug called aromatase inhibitors improved overall survival. "A lot of people have been waiting to see whether aromatase inhibitors will show a survival advantage, and I think these data will assure them that five years of tamoxifen is no longer the standard of care ... ," said Walter Jonat, professor at the University of Kiel in Germany.

read more | 1786 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 04:49 PM.